JBCHEPHARMJBCHEPHARMNSE
Amalgamation
As filed · Amalgamation/Merger
M&AWatchMajormateriality 79 out of 100
What happened
FactAmalgamation/Merger. Chemicals & Pharmaceuticals Limited. lakh eighty one thousand five hundred and nineteen) equity shares (representing 46.39% of the.
Why it matters
CapitSignal interpretationA merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
RevisedEarlierFY25
India and CDMO business should constitute around 75% - 80% of total revenue in the mid-term
NowFY25
India business should continue to deliver market-beating growth; Focus on increasing chronic share to 60% in the mid to long-term
Change
FactTarget revision
Implication
CapitSignal interpretationThe earlier statement indicated that India and CDMO business would constitute around 75% - 80% of total revenue, while the current statement focuses solely on the India business aiming for a chronic share of 60%. This represents a material change in the target for the revenue contribution.
Watch next
Fact- Swap ratio and its valuation basis
- Regulatory and NCLT approvals required
- Appointed date
- By end of quarter 3, you should see that business growing at high single digit. (management committed by Q3 FY27)
- the second phase of our pipeline starts getting approvals from H2 of next financial year. (management committed by H2 FY27)
Evidence
- JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Amalgamation/Merger(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · FY25
How CapitSignal classified this
- Reasoning:
- MERGER base 74; +2 corroborating keywords; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%